Intravitreal Devices for the Treatment of Vitreous Inflammation
The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/126463 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552420884873216 |
|---|---|
| author | John B. Christoforidis Susie Chang Angela Jiang Jillian Wang Colleen M. Cebulla |
| author_facet | John B. Christoforidis Susie Chang Angela Jiang Jillian Wang Colleen M. Cebulla |
| author_sort | John B. Christoforidis |
| collection | DOAJ |
| description | The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined. |
| format | Article |
| id | doaj-art-3c844ea1d0d64501b2178263a2cd83fe |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-3c844ea1d0d64501b2178263a2cd83fe2025-02-03T05:58:45ZengWileyMediators of Inflammation0962-93511466-18612012-01-01201210.1155/2012/126463126463Intravitreal Devices for the Treatment of Vitreous InflammationJohn B. Christoforidis0Susie Chang1Angela Jiang2Jillian Wang3Colleen M. Cebulla4Retina Division, Department of Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USADepartment of Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USADepartment of Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USADepartment of Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USADepartment of Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USAThe eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined.http://dx.doi.org/10.1155/2012/126463 |
| spellingShingle | John B. Christoforidis Susie Chang Angela Jiang Jillian Wang Colleen M. Cebulla Intravitreal Devices for the Treatment of Vitreous Inflammation Mediators of Inflammation |
| title | Intravitreal Devices for the Treatment of Vitreous Inflammation |
| title_full | Intravitreal Devices for the Treatment of Vitreous Inflammation |
| title_fullStr | Intravitreal Devices for the Treatment of Vitreous Inflammation |
| title_full_unstemmed | Intravitreal Devices for the Treatment of Vitreous Inflammation |
| title_short | Intravitreal Devices for the Treatment of Vitreous Inflammation |
| title_sort | intravitreal devices for the treatment of vitreous inflammation |
| url | http://dx.doi.org/10.1155/2012/126463 |
| work_keys_str_mv | AT johnbchristoforidis intravitrealdevicesforthetreatmentofvitreousinflammation AT susiechang intravitrealdevicesforthetreatmentofvitreousinflammation AT angelajiang intravitrealdevicesforthetreatmentofvitreousinflammation AT jillianwang intravitrealdevicesforthetreatmentofvitreousinflammation AT colleenmcebulla intravitrealdevicesforthetreatmentofvitreousinflammation |